Brooks Gabriel 4
4 · Solid Biosciences Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Solid Biosciences (SLDB) CMO Brooks Gabriel Receives RSUs, Sells to Cover
What Happened
- Dr. Brooks Gabriel, Chief Medical Officer of Solid Biosciences (SLDB), had 10,937 restricted stock units (RSUs) convert into common shares on Feb 13, 2026. These were RSU vesting/convertible-derivative transactions (reported as "M" — exercise/conversion of derivative).
- Following the vesting, a sell-to-cover transaction to satisfy withholding taxes was executed (reported with a weighted average sale price of $5.82, range $5.23–$6.14). The filing indicates the sell-to-cover was automatic under a previously adopted instruction and not a discretionary trade.
Key Details
- Transaction dates: RSU conversion — Feb 13, 2026; sell-to-cover execution — Feb 18, 2026.
- Shares converted: 10,937 RSUs converted into 10,937 common shares (acquired via conversion).
- Sale details: weighted average sale price reported $5.82; price range $5.23–$6.14. The filing notes the sale was to cover tax withholding under a durable automatic sales instruction (sell-to-cover).
- Footnotes: F1 explains each RSU equals a contingent right to one common share; F2 confirms the sale was to cover withholding taxes and not a discretionary trade; F4 notes the RSUs were granted 2/13/2024 and vest 25% each anniversary for four years.
- Shares owned after transaction: not specified in the provided excerpt of the filing.
- Filing timeliness: Form filed Feb 18, 2026 for transactions on Feb 13, 2026 — appears to be timely (within SEC Form 4 reporting window).
Context
- This was a routine vesting of previously granted RSUs with an automatic sell-to-cover for taxes. Such sell-to-cover transactions are common and reflect tax withholding, not necessarily a discretionary sell signal by the insider.
- The conversion of RSUs is not a market purchase; it’s the issuance of shares upon vesting.
Insider Transaction Report
Form 4
Brooks Gabriel
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-02-13+10,937→ 95,029 total - Sale
Common Stock
[F2][F3]2026-02-18$5.82/sh−0$0→ 89,466 total - Exercise/Conversion
Restricted Stock Units
[F1][F4]2026-02-13−10,937→ 21,876 total→ Common Stock (10,937 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
- [F2]This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
- [F4]The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Signature
/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks|2026-02-18